Intra Cellular Therapies reported $135.36M in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US USD 154.84M 15.01M
Aptinyx Inc APTX:US USD 66.58M 18.68M
Biocryst Pharmaceuticals BCRX:US USD 461.19M 43.71M
Biogen BIIB:US USD 3.68B 1.03B
Bristol Myers Squibb BMY:US USD 7.73B 3.02B
Cytokinetics CYTK:US USD 106.24M 12.61M
Esperion Therapeutics ESPR:US USD 159.4M 36.46M
Gilead Sciences GILD:US USD 4.7B 40M
Halozyme Therapeutics HALO:US USD 147.16M 56.23M
Intra Cellular Therapies ITCI:US USD 135.36M 58.12M
Jazz Pharmaceuticals JAZZ:US USD 482.67M 191.74M
Marinus Pharmaceuticals MRNS:US USD 168.25M 75.92M
Minerva Neurosciences NERV:US USD 40.22M 9.53M
Nektar Therapeutics NKTR:US USD 105.76M 28.21M
Neurocrine Biosciences NBIX:US USD 212.2M 48.9M
Prothena PRTA:US USD 495.63M 13.17M
Supernus Pharmaceuticals SUPN:US USD 111.49M 61.94M
United Therapeutics UTHR:US USD 966.8M 171.6M
Vanda Pharmaceuticals VNDA:US USD 49.4M 8.83M